CatalYm, a Munich, Germany-based biotechnology company, raised €50M in Series C funding.
The round was led by Brandon Capital and Jeito Capital with participation from Forbion, Novartis Venture Fund, Vesalius Biocapital III, Bayern Kapital, BioGeneration Ventures and Coparion. n conjunction with the close of the Series C financing, Dr. Jonathan Tobin, Partner at Brandon Capital and Dr. Andreas Wallnoefer, Partner at Jeito Capital will join CatalYm’s Board of Directors.
The company intends to use the funds to support the continued, promising clinical development of its lead candidate, visugromab, a humanized monoclonal antibody engineered to neutralize the tumor-produced Growth Differentiation Factor-15 (GDF-15). GDF-15 acts as a key regulator of immune cell activation and as an inhibitor of immune cell infiltration into the tumor tissue.
Led by CEO Dr. Phil L’Huillier, CatalYm has identified GDF-15 as a central regulator of the immune system in the tumor microenvironment. The company is focused on reversal of GDF-15-mediated immunosuppression to induce a potent antitumoral immune reaction in non-responsive tumors. Its lead program visugromab is poised to demonstrate clinical proof-of-concept in multiple solid tumor indications which will expand the treatment horizon for current and future immunotherapies.
FinSMEs
22/11/2022